{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:25:26Z","timestamp":1790162726792,"version":"4.1.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.jcf.2019.12.006","type":"journal-article","created":{"date-parts":[[2019,12,14]],"date-time":"2019-12-14T23:00:54Z","timestamp":1576364454000},"page":"415-420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Lumacaftor\/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease"],"prefix":"10.1016","volume":"19","author":[{"given":"Koliarne","family":"Tong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"France","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Burr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"Greville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Middleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Wainwright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Dorahy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5676-6126","authenticated-orcid":false,"given":"Peter","family":"Wark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.jcf.2019.12.006_bib0001","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1258\/jrsm.2012.12s001","article-title":"Cystic fibrosis transmembrane conductance regulator dysfunction and its treatment","volume":"105","author":"Hull","year":"2012","journal-title":"J R Soc Med"},{"issue":"46","key":"10.1016\/j.jcf.2019.12.006_bib0002","doi-asserted-by":"crossref","first-page":"18843","DOI":"10.1073\/pnas.1105787108","article-title":"Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809","volume":"108","author":"Van Goor","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"18","key":"10.1016\/j.jcf.2019.12.006_bib0003","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMc1510466","article-title":"Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jcf.2019.12.006_bib0004","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S2213-2600(14)70218-8","article-title":"Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the gly551asp-cftr mutation: a phase 3, open-label extension study (PERSIST)","volume":"2","author":"McKone","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"8","key":"10.1016\/j.jcf.2019.12.006_bib0005","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S2213-2600(16)30121-7","article-title":"Efficacy and safety of lumacaftor\/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis","volume":"4","author":"Elborn","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2019.12.006_bib0006","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jcf.2018.07.011","article-title":"Lumacaftor\/Ivacaftor reduces pulmonary exacerbations irrespective of initial changes in FEV1","volume":"18","author":"McColley","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2019.12.006_bib0007","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jcf.2017.02.009","article-title":"Immediate effects of lumacaftor\/ivacaftor administration on lung function in patients with severe cystic fibrosis lung disease","volume":"16","author":"Popowicz","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2019.12.006_bib0008","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jcf.2015.10.006","article-title":"IV-treated pulmonary exacerbations in the prior year: an important independent risk factor for future pulmonary exacerbation in cystic fibrosis","volume":"15","author":"VanDevanter","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.jcf.2019.12.006_bib0009","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1136\/thx.2011.161117","article-title":"Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis","volume":"66","author":"de Boer","year":"2011","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.jcf.2019.12.006_bib0010","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1080\/03007995.2016.1277196","article-title":"Frequency and costs of pulmonary exacerbations in patients with cystic fibrosis in the United States","volume":"33","author":"Rubin","year":"2017","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.jcf.2019.12.006_bib0011","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1378\/chest.123.1.20","article-title":"Factors influencing outcomes in cystic fibrosis: a center-based analysis","volume":"123","author":"Johnson","year":"2003","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.jcf.2019.12.006_bib0012","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jcf.2017.10.005","article-title":"Do cystic fibrosis centres with the lowest FEV1 still use the least amount of intravenous antibiotics? a registry-based comparison of intravenous antibiotic use among adult CF centres in the UK","volume":"17","author":"Hoo","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"21","key":"10.1016\/j.jcf.2019.12.006_bib0013","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jcf.2019.12.006_bib0014","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jcf.2017.09.012","article-title":"Lumacaftor\/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for <em>F508del-CFTR<\/em>","volume":"17","author":"Taylor-Cousar","year":"2018","journal-title":"J Cyst Fibrosis"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199319309853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199319309853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:42:56Z","timestamp":1761601376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199319309853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S1569199319309853"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2019.12.006","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lumacaftor\/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2019.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2019 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}